Literature DB >> 24591918

Effect of GnRH analogues and octreotide treatment on apoptosis and the cell proliferation of endometrium adenocarcinoma cell lines.

Harika Bodur Oztürk1, Birol Vural2, Eray Calışkan2, Seyhun Solakoğlu3.   

Abstract

OBJECTIVE: The aim of this study was to compare apoptotic and antiproliferative effects of gonadotropin-releasing hormone analogues and their combination with octeotide on endometrioid endometrial cancer cell lines. MATERIAL AND
METHOD: Women diagnosed with endometrioid adenocarcinoma at the department of Gynecology and Obstetric of Kocaeli University Medical School were included in this research. Endometrium cancer cell lines obtained from three patients were used for this study. After trypsinization in 0.5% in calcium magnesium, free phosphate buffer solution (CMFPBS) cells were seeded on glass slides in 24-well plates containing DMEM-F12 medium and 10% fetal calf serum as culture medium. Cells were incubated for 24 hours at 37ºC in 5% CO2. GnRH agonist leuprolide (Lucrin 1 μmol/L), GnRH antagonist ganirelix (Orgalutran 1 μmol/L), leuprolide with octreotide (Sandostatin 10-6 mol/L), ganirelix with octreotide and no drug were added to the wells. Apoptosis and cells proliferations were evaluated after 12, 24, 48 and 72(th) hours of incubation. The percentage of apoptotic cells was evaluated by TdT mediated biotin-dUTP nick-end labeling (TUNEL) method; cell proliferation was assessed by bromodeoxyuridine (BrdU) incorporation.
RESULTS: Apoptotic index in grade I EEC cell line among ganirelixoctreotide treated cells and leuprolide-octreotide combination therapy were respectively higher than the untreated control (p<0.001, p=0.001). The number of apoptotic cells in grade II EEC cell line among leuprolide-octreotide and leuprolide were significantly (p<0.001, p<0.001) higher than in controls. In grade III EEC cell line, the number of TUNEL positive cells among leuprolide, ganirelix and ganirelixoctreotide therapiy groups were significantly higher than in untreated control. Time dependent antiproliferative effect was obtained with leuprolide and leuprolide-octreotide in grade I EEC (p<0.001, p<0.001). Grade II EEC cell line is not influenced by hormonotherapies. However, the antiproliferative effect was obtained with ganirelix, leuprolide and leuprolide-octreotide in grade III cell line.
CONCLUSION: GnRH analogues appears to have a direct effect, enhancing the apoptotic index and decreasing the cell proliferation in endometrial adenocancer cell lines.

Entities:  

Keywords:  Endometrial cancer; apoptosis; cell proliferation; gonadotropin-releasing hormone analogues; octreotide

Year:  2010        PMID: 24591918      PMCID: PMC3939219          DOI: 10.5152/jtgga.2010.19

Source DB:  PubMed          Journal:  J Turk Ger Gynecol Assoc        ISSN: 1309-0380


  27 in total

1.  Apoptosis in the endometrium.

Authors:  M J Arends
Journal:  Histopathology       Date:  1999-08       Impact factor: 5.087

Review 2.  Hormonal treatment of endometrial cancer.

Authors:  G Emons; W Heyl
Journal:  J Cancer Res Clin Oncol       Date:  2000-11       Impact factor: 4.553

3.  Treatment of breast cancer with gonadotropin-releasing hormone.

Authors:  A Manni; R Santen; H Harvey; A Lipton; D Max
Journal:  Endocr Rev       Date:  1986-02       Impact factor: 19.871

Review 4.  Gonadotropin-releasing-hormone-receptor antagonists.

Authors:  J A Huirne; C B Lambalk
Journal:  Lancet       Date:  2001-11-24       Impact factor: 79.321

5.  Inhibitory effect of luteinising hormone-releasing hormone analogues on human endometrial cancer in vitro.

Authors:  I Noci; M Coronnello; P Borri; E Borrani; M Giachi; O Chieffi; M Marchionni; M Paglierani; A M Buccoliero; A Cherubini; A Arcangeli; E Mini; G Taddei
Journal:  Cancer Lett       Date:  2000-03-13       Impact factor: 8.679

6.  Direct growth inhibition of human endometrial cancer cells by the gonadotropin-releasing hormone antagonist SB-75: role of apoptosis.

Authors:  D Kleinman; A Douvdevani; A V Schally; J Levy; Y Sharoni
Journal:  Am J Obstet Gynecol       Date:  1994-01       Impact factor: 8.661

Review 7.  Intracellular actions of gonadotropic and peptide hormones and the therapeutic value of GnRH-agonists in ovarian cancer.

Authors:  G Emons; O Ortmann; G S Pahwa; R Hackenberg; F Oberheuser; K D Schulz
Journal:  Acta Obstet Gynecol Scand Suppl       Date:  1992

8.  High affinity binding and direct antiproliferative effects of luteinizing hormone-releasing hormone analogs in human endometrial cancer cell lines.

Authors:  G Emons; B Schröder; O Ortmann; S Westphalen; K D Schulz; A V Schally
Journal:  J Clin Endocrinol Metab       Date:  1993-12       Impact factor: 5.958

9.  Gonadotropin-releasing hormone type II induces apoptosis of human endometrial cancer cells by activating GADD45alpha.

Authors:  Hsien-Ming Wu; Jung-Chien Cheng; Hsin-Shih Wang; Hong-Yuan Huang; Colin D MacCalman; Peter C K Leung
Journal:  Cancer Res       Date:  2009-04-14       Impact factor: 12.701

10.  Frequent expression of immunoreactive somatostatin receptors in cervical and endometrial cancer.

Authors:  Solveig Schulz; Johannes Schmitt; Wolfgang Weise
Journal:  Gynecol Oncol       Date:  2003-06       Impact factor: 5.482

View more
  2 in total

1.  Association of endothelial nitric oxide synthase gene polymorphisms with endometrial carcinoma: a preliminary study.

Authors:  Ebru Oztürk; Ebru Dikensoy; Ozcan Balat; Mete Gürol Uğur; Sibel Oğuzkan Balcı; Abdullah Aydın; Ulkü Kazancı; Sacide Pehlivan
Journal:  J Turk Ger Gynecol Assoc       Date:  2011-12-01

Review 2.  The Role of Gonadotropin-Releasing Hormone (GnRH) in Endometrial Cancer.

Authors:  Günter Emons; Carsten Gründker
Journal:  Cells       Date:  2021-02-01       Impact factor: 6.600

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.